Skip to main content
TEYI PHARMACEUTICAL GROUP CO.,LTD logo

TEYI PHARMACEUTICAL GROUP CO.,LTD — Investor Relations & Filings

Ticker · 002728 ISIN · CNE100001WK6 LEI · 300300ZUIZCFPGQWOZ61 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,596 across all filing types
Latest filing 2017-03-27 Audit Report / Informat…
Country CN China
Listing Shenzhen Stock Exchange 002728

About TEYI PHARMACEUTICAL GROUP CO.,LTD

https://www.tczy.com.cn

TEYI PHARMACEUTICAL GROUP CO.,LTD. specializes in the research, development, manufacturing, and distribution of pharmaceutical products. The company's portfolio primarily consists of Chinese patent medicines and chemical drug preparations. Its flagship product, Zhike Bao Tablets, is widely recognized for treating chronic bronchitis and cough-related ailments. Beyond respiratory health, the group produces a diverse range of medications covering cardiovascular diseases, gastrointestinal disorders, and anti-infective treatments. Teyi Pharmaceutical operates modern production facilities and maintains a robust distribution network to serve healthcare providers and pharmacies. The company emphasizes the integration of traditional medicinal knowledge with modern pharmaceutical technology to enhance product efficacy and safety.

Recent filings

Filing Released Lang Actions
国信证券股份有限公司关于公司2016年度募集资金存放与使用情况的核查意见
Audit Report / Information Classification · 95% confidence The document is a detailed report from Guosen Securities (the sponsor) on the 2016 annual verification of the deposit and use of raised funds by Te Yi Pharmaceutical Group Co., Ltd. It includes extensive financial data on the amount raised, usage, changes in investment projects, and compliance with regulatory requirements. It also contains an auditor's opinion on the annual report of raised funds usage. The document is not a general annual report (10-K) but a specialized verification report focused on the use and management of raised funds, which aligns with the definition of an Audit Report / Information (AR). The length and detail confirm it is the report itself, not just an announcement. Therefore, the appropriate classification is AR with high confidence. FY 2016
2017-03-27 Chinese
关于公司募集资金年度存放与实际使用情况的鉴证报告
Regulatory Filings
2017-03-27 Chinese
2016年年度报告
Annual Report Classification · 100% confidence The document is titled as the 2016 Annual Report of Teyi Pharmaceutical Group Co., Ltd. It contains detailed sections typical of an annual report, including company overview, financial data, business analysis, management discussion, and future outlook. The document covers the full fiscal year 2016 (January 1 to December 31) and includes comprehensive financial performance data, management analysis, and operational details. The length of the document (15,000 characters) and the presence of extensive financial and operational information confirm it is the full annual report rather than a brief announcement or summary. Therefore, the document fits the definition of an Annual Report (10-K). FY 2016
2017-03-27 Chinese
2016年度内部控制自我评价报告
Audit Report / Information Classification · 95% confidence The document is titled '2016 年度内部控制自我评价报告' which translates to '2016 Annual Internal Control Self-Evaluation Report'. It is a detailed report on the company's internal control evaluation for the fiscal year ending December 31, 2016. The content includes descriptions of internal control scope, evaluation criteria, defect classifications, and conclusions about the effectiveness of internal controls. It is not an announcement or a brief summary but a substantive report containing detailed internal control assessment information. This type of document aligns with an Audit Report / Information (AR) as it focuses on internal control evaluation and related audit matters rather than a full annual report or other categories. The document length (7442 characters) supports it being a full report rather than a short announcement. Therefore, the appropriate classification is AR with high confidence. FY 2016
2017-03-27 Chinese
独立董事关于相关事项的独立意见
Audit Report / Information Classification · 95% confidence The document is an independent directors' opinion on various company matters including related party transactions, external guarantees, profit distribution plan, use of raised funds, internal control evaluation, and appointment of senior management for the year 2016. It references compliance with regulatory guidelines and company bylaws, and provides independent opinions rather than full financial statements or detailed financial results. The document length is relatively short (2424 characters) and it serves as an independent opinion report rather than a full annual report or audit report. It does not contain financial statements or detailed financial data, nor is it a simple announcement or certification. The content aligns with a report providing audit-related opinions and compliance confirmations, typical of an Audit Report / Information filing rather than a full Annual Report or Management Report. Therefore, the best classification is Audit Report / Information (AR). FY 2016
2017-03-27 Chinese
关于第三届监事会第十次会议决议的公告
Regulatory Filings Classification · 95% confidence The document is a formal announcement of resolutions passed at the 10th meeting of the 3rd Supervisory Board of 特一药业集团股份有限公司. It includes voting results on various proposals such as the 2016 Supervisory Board Work Report, 2016 Financial Final Accounts Report, 2016 Profit Distribution Plan, 2016 Annual Report, Internal Control Self-Evaluation Report, and other financial and operational matters. The document states that these proposals still need to be submitted to the shareholders' meeting for approval. The document is short (1350 characters) and serves as an official announcement of meeting resolutions rather than the full reports themselves. It does not contain detailed financial statements or substantive financial data but rather the outcomes of supervisory board deliberations and approvals. Therefore, it is best classified as a Regulatory Filing (RNS) because it is a general regulatory announcement of meeting resolutions and not a full report or a voting result announcement from a shareholders meeting.
2017-03-27 Chinese

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.